You are here: Industry Insights > SARS-CoV-2

News List

Tonix and Southern Research to study immune responses to Covid-19 pharmaceutical-technology
June 19, 2020
Tonix Pharmaceuticals has expanded its ongoing partnership with non-profit Southern Research to study T-cell immune responses to SARS-CoV-2, the novel coronavirus that causes Covid-19.
Study reveals COVID-19 virus can cause collapse of respiratory centre in brain expresspharma
June 19, 2020
May infect PreBötzinger complex (PBC), primary centre of the brain that controls respiratory rhythm generation.
Nanosponges could intercept coronavirus infection worldpharmanews
June 18, 2020
Nanoparticles cloaked in human lung cell membranes and human immune cell membranes can attract and neutralize the SARS-CoV-2 virus in cell culture, causing the virus to lose its ability to hijack host cells and reproduce.
Cepheid Announces Development of Combination Test for SARS-CoV-2, Flu A, Flu B, RSV americanpharmaceuticalreview
June 18, 2020
Cepheid announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19 during the upcoming respiratory virus season.
CureVac Receives Approval to Initiate Clinical Trial of SARS-CoV-2 Vaccine Candidate contractpharma
June 18, 2020
The Belgian Federal Agency for Medicines and Health Products (FAMHP) has approved the Phase 1 clinical trial for CureVac’s vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.
Promising path found for COVID-19 therapeutics worldpharmanews
June 17, 2020
A team of researchers at the University of Georgia has successfully demonstrated that a set of drug-like small molecules can block the activity of a key SARS-CoV-2 protein - providing a promising path for new COVID-19 therapeutics.
Up to 45 percent of SARS-CoV-2 infections may be asymptomatic worldpharmanews
June 17, 2020
An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a Scripps Research analysis of public datasets on asymptomatic infections.
Super-potent human antibodies protect against COVID-19 in animal tests worldpharmanews
June 17, 2020
A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus that causes the disease, when tested in animals and human cell cultures.
Scientists discover new super-potent human antibodies that can protect against COVID-19 expresspharma
June 17, 2020
These antibodies may also be used to provide temporary, vaccine-like protection against SARS-CoV-2 infection for healthcare workers, elderly people, and others who respond poorly to traditional vaccines.
Grifols Begins Production of Anti-SARS-CoV-2 Hyperimmune Immunoglobulin contractpharma
June 16, 2020
Potential anti-COVID-19 passive immune therapy is part of a collaboration with the U.S. government, first doses for trials are expected July 2020.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page